Modified Electrospun Modified Electrospun Nylon6/ Poly(ethylene oxide) Nanofibers for Detection of Clinical Colon Cancer

碩士 === 國立臺灣科技大學 === 材料科學與工程系 === 103 === In this study, we designed an electrospinning composite nanofiber to capture colon circulating tumor cells (CTCs) from peripheral blood of colon cancer patients. Detection of CTCs is always interfered by lots of leukocyte contaning in human blood. We introduc...

Full description

Bibliographic Details
Main Authors: Fu-Hsiang Lin, 林復翔
Other Authors: Jem-Kun Chen
Format: Others
Language:zh-TW
Published: 2015
Online Access:http://ndltd.ncl.edu.tw/handle/91408584519200846655
Description
Summary:碩士 === 國立臺灣科技大學 === 材料科學與工程系 === 103 === In this study, we designed an electrospinning composite nanofiber to capture colon circulating tumor cells (CTCs) from peripheral blood of colon cancer patients. Detection of CTCs is always interfered by lots of leukocyte contaning in human blood. We introduced nylon-6 and poly(ethylene oxide)(PEO) to electrospin as nanofiber membranes. Nylon-6 is a substrate which can avoid the nanofibers to dissolve in aqueous solution. PEO and derivatives are anti-fouling material to prevent leukocyte fouling. For grafting amine groups, PEO is modified with (3-aminopropyl)triethoxysilane (APTES). Amine groups are media to fix antibody biotin(EpCAM biotin) to caught the CTCs. The result suggest that the radio of Nylon6/PEO is 30/70. After testing, we find nanofibers possessing the ability to antifoul of leukocyte. The efficiency is 90%. Colon cancer cell line (HCT-116,DLD-1,SAS and Hela), 10 to 100000 colon cancer cells, are mixed in 0.3ml medium to perform the capture of CTCs. The results show that detection of efficiency increase linearly upon 70%. Finally, we started clinical tests for 21 times. If the blood come from colon cancer patients, we will find CTCs. There are some advantage in our nanofibers. For example, we will know the result in the short time,and the cost of nanofibers are very low. We trust our nanofibers possessing high potential being a new reference for colon cancer patients like CEA.